ArticleHaematologica2018
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.International journal of hematology · 2021Trial
- Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.Bone marrow transplantation · 2026Article
- Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties.Hematological oncology · 2025Review
- Exploration of treatment-free remission in CML, based on molecular monitoring.Cancer medicine · 2024Review
- Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia.Scientific reports · 2023Article
- Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.Cells · 2023Review
- Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing.PLOS global public health · 2023Article
- Clinically relevant fusion oncogenes: detection and practical implications.Therapeutic advances in medical oncology · 2022Review
- Article
- Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia.Cancers · 2021Review
- Article
- Treatment-free remission in patients with chronic myeloid leukaemia.Nature reviews. Clinical oncology · 2020Review
- Influence of majorOncotarget · 2020Article
- Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.Leukemia · 2020Article
- Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.Cancer management and research · 2020Review
- Review
- Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.Leukemia · 2019Review
- Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia.Journal of cellular and molecular medicine · 2019Article
- Response to Imatinib therapy is inferior for e13a2BMC hematology · 2019Article
- Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.Leukemia · 2018Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate quantification of minimal residual disease (MRD) during treatment of chronic myeloid leukemia (CML) guides clinical decisions. The conventional MRD method, RQ-PCR for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.